Amicus Therapeutics — Technical Presentation (October 2019)
17 slides from Amicus Therapeutics's technical presentation, Oct 2, 2019
Slide 1: First-in-Human Study of ATB200/AT2221 in Patients With Pompe Disease: 24-Month Functional Assessment Results
First - in - Human Study of ATB200/AT2221 in Patients With Pompe Disease: 24 - Month Functional Assessment Results From the ATB200 - 02 Trial Benedikt Schoser , 1 Priya Kishnani, 1 Drago Bratkovic, 3 Barry J. Byrne, 4 Paula R. Clemens, 5 Ozlem Goker - Alpan, 6 Xue Ming, 7 Mark Roberts, 8 Peter Schwe
Slide 2: Disclosure Statement of Financial Interest
2 Disclosure Statement of Financial Interest ▪ Advisory Board: Audentes Therapeutics, Sanofi - Genzyme, Lupin therapeutics, Nexien Biopharm ▪ Speaker’s Bureau: Sanofi Genzyme, Kedrion ▪ Research Grant : Sanofi Genzyme, Greenovation biopharm
Slide 3: Overview of Pompe Disease
3 Overview of Pompe Disease ▪ An inherited lysosomal disorder caused by GAA deficiency 1,2 ▪ Characterized by progressive accumulation of lysosomal glycogen, primarily in striated muscle 1,2 ▪ A spectrum of disease severity, including organ failure and/or death 1 ▪ Can develop at various life stages
Slide 4: ATB200/AT2221: A Novel Therapy for Pompe Disease
4 ATB200/AT2221: A Novel Therapy for Pompe Disease ▪ Novel investigational approach: coadministration of 2 distinct agents ̶ ATB200: investigational next - generation ERT • Designed with optimized glycosylation and high levels of mannose 6 - phosphate residues for better uptake to disease - relevant
Slide 5: ATB200-02 Study Design (NCT02675465)
5 ATB200 - 02 Study Design (NCT02675465) • Phase 1/2 study to evaluate safety, tolerability, PK, PD, and efficacy of ATB200/AT2221 in adults with Pompe disease a 18 - Week Primary Treatment Period With Long - Term Extension Stage 1 (6 wks ) Stage 2 (12 wks ) Stage 3 (2 yrs , ongoing) ATB200 single -
Slide 6: Baseline Characteristics
6 Baseline Characteristics 6MWT=6 - minute walk test; ERT=enzyme replacement therapy; FVC=forced vital capacity; NA=not applicable; SD=standard deviation. a Cohort 2 patients were required to have been on alglucosidase alfa for ≥2 years at baseline. b n=3. Data from interim analysis 8. Cohort 1 ERT
Slide 7: 6-Minute Walk Test
7 6 - Minute Walk Test Cohorts 1 and 3 ▪ 6MWT increased in 7/10, 9/10, and 8/9 ERT - switch patients at Months 6, 12, and 24, respectively ▪ 6MWT increased in 5/5, 5/5, and 5/5 ERT - naive patients at Months 6, 12, and 24, respectively 6MWT=6 - Minute Walk Test; ERT=enzyme replacement therapy; SD=st
Slide 8: Sitting Forced Vital Capacity (FVC, % Predicted)
8 Sitting Forced Vital Capacity (FVC, % Predicted) On average, FVC remained stable in ERT - switch patients and increased in ERT - naive patients ▪ FVC was stable or increased in 5/8 ERT - switch patients at Month 24 (2 - 6 yrs on ERT); MIP was stable and MEP increased ▪ FVC was stable or increased
Slide 9: Manual Muscle Test Score
9 Manual Muscle Test Score Increases were observed in manual muscle strength a in Cohorts 1 – 3 at Month 6 and Month 12, and in Cohorts 1 and 2 at Month 24 ▪ Quantitative muscle strength testing h results were generally consistent with manual muscle test results Cohort Body Area Baseline Change From
Slide 10: Timed Motor Function Tests
10 Timed Motor Function Tests ERT=enzyme replacement therapy; GSGC=Gait, Stairs, Gowers, Chair; SD=standard deviation. a One patient in Cohort 1 discontinued after 18 weeks due to burden of travel; baseline value is not shown for this patient. b One patient in Cohort 1 discontinued from study before
Slide 11: Fatigue Severity Scale Patient-Reported Outcome Instrument
11 Fatigue Severity Scale Patient - Reported Outcome (PRO) Instrument All cohorts were significantly impacted by fatigue at baseline and demonstrated improvements in fatigue over time Cohort Max score=63 Baseline Change From Baseline Month 6 Month 12 Month 24 mean (SD) n mean (SD) n mean (SD) n mean
Slide 12: Clinical Assessments Summary for Cohort 4 ERT-Switch (≥7 yrs on ERT)
12 Clinical Assessments Summary for Cohort 4 ERT - Switch (≥7 yrs on ERT) Improvements seen in majority of the patients both on motor function and strength as well as pulmonary function as assessed by FVC after 3 - 15 months of treatment Cohort 4 Baseline CFBL to 6M CFBL to LOCF mean (SD) n mean (SD
Slide 13: Subject Global Impression of Change: Overall Physical Well-being
13 Subject Global Impression of Change: Overall Physical Well - being Improvements in overall physical well - being in all four cohorts Cohort 1 9 10 10 10 9 9 9 Cohort 2 5 5 4 4 4 4 5 Cohort 3 5 5 5 5 5 5 5 Cohort 4 5 3 3 1 SGIC Score 7 6 5 4 3 2 1 0 n M6 M9 M12 M15 M18 M21 M24 Cohort 1: ERT - swit
Slide 14: Muscle Damage and Disease Substrate Biomarkers
14 Muscle damage and disease substrate biomarkers CK=creatine kinase; Hex4=urine hexose tetrasaccharide ; SE=standard error. Persistent improvement in biomarkers of muscle damage (CK) and disease substrate (Hex4) in all cohorts Percentage Change From Baseline for Hex4 Visit BL M3 M6 M9 M12 M15 M18 M
Slide 15: Safety Summary
15 Safety Summary ▪ As of August 28, 2019, the longest treatment duration was 40 months ▪ Most treatment - emergent AEs were transient and generally mild or moderate in severity ▪ 11 serious AEs a (3 severe, 8 moderate) occurred in 7 patients ̶ 6 events, all IARs (in 3 patients) were considered prob
Slide 16: Conclusions
16 Conclusions ▪ Data from this interim analysis show functional benefit of ATB200/AT2221 in patients with Pompe disease out to 24 months for cohorts 1,2 and 3 ̶ 6MWT and pulmonary function improved with continued benefit observed to Months 24 ̶ Patients reported decreased fatigue and felt improved
Slide 17: Acknowledgments
17 Acknowledgments ▪ The authors thank the patients, their families, and Pompe disease patient organizations, as well as the study investigators ▪ ATB200 - 02 investigators: Paula R. Clemens, Drago Bratkovic , Barry J. Byrne, Ozlem Goker - Alpan , Mark Roberts, Peter Schwenkreis , Kumaraswamy Sivaku
Amicus Therapeutics — Technical Presentation (October 2019) on 6ix